Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schor, S. L.
Right arrow Articles by Kay, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schor, S. L.
Right arrow Articles by Kay, R. A.
[Cancer Research 63, 8827-8836, December 15, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Migration-Stimulating Factor

A Genetically Truncated Onco-Fetal Fibronectin Isoform Expressed by Carcinoma and Tumor-Associated Stromal Cells

Seth L. Schor1, Ian R. Ellis1, Sarah J. Jones1, Robin Baillie1, Kanjula Seneviratne1, Julia Clausen1, Katsumi Motegi1, Borek Vojtesek2, Katerina Kankova1, Elizabeth Furrie3, Mark J. Sales4, Ana M. Schor1 and Richard A. Kay1

1 Unit of Cell and Molecular Biology, The Dental School, University of Dundee, Dundee, Scotland;
2 Masaryk Memorial Cancer Institute, Brno, Czech Republic; and Departments of
3 Molecular and Cellular Pathology and
4 Cytogenetics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland

Migration-stimulating factor (MSF) is a 70-kDa motogenic protein previously reported to be expressed by fetal and cancer patient fibroblasts cultured in vitro and present in the serum of breast cancer patients. A 2.2-kb full-length MSF cDNA has been cloned and shown to be a truncated isoform of fibronectin generated from its primary gene transcript by a hitherto unrecognized intron read-through mechanism. MSF cDNA is identical to the 5' end of fibronectin cDNA, up to and including exon III-1a, and terminates in a novel 195-nucleotide 3' sequence. This MSF unique sequence is derived from the intron immediately downstream of exon III-1a in the fibronectin gene and is not found in any previously identified "full-length" fibronectin cDNA. MSF mRNA is 1000-fold less abundant than full-length fibronectin message in fetal fibroblasts and exhibits rapid biphasic decay kinetics previously associated with oncogenes and stress response molecules. MSF recombinant protein exhibits a potent and substratum-dependent motogenic activity, with half-maximal response manifest at 0.1–1.0 pg/ml. This activity is (a) mediated by the IGD amino acid motif; and (b) not expressed by (i.e., cryptic within) full-length fibronectin. In situ hybridization and immunohistochemistry confirm that MSF is expressed by tumor-associated fibroblasts and additionally indicate that it is also expressed by carcinoma cells and tumor-associated vascular endothelial cells. MSF, as a consequence of its potent bioactivities and expression by both stromal and carcinoma cell populations, is well placed to function as an epigenetic effector promoting cancer development.




This article has been cited by other articles:


Home page
Genes Dev.Home page
J. Wels, R. N. Kaplan, S. Rafii, and D. Lyden
Migratory neighbors and distant invaders: tumor-associated niche cells
Genes & Dev., March 1, 2008; 22(5): 559 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Millard, I. R. Ellis, A. R. Pickford, A. M. Schor, S. L. Schor, and I. D. Campbell
The Role of the Fibronectin IGD Motif in Stimulating Fibroblast Migration
J. Biol. Chem., December 7, 2007; 282(49): 35530 - 35535.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Tomkowicz, K. Rybinski, B. Foley, W. Ebel, B. Kline, E. Routhier, P. Sass, N. C. Nicolaides, L. Grasso, and Y. Zhou
Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration
PNAS, November 13, 2007; 104(46): 17965 - 17970.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. Sandal, K. Valyi-Nagy, V. A. Spencer, R. Folberg, M. J. Bissell, and A. J. Maniotis
Epigenetic Reversion of Breast Carcinoma Phenotype Is Accompanied by Changes in DNA Sequestration as Measured by AluI Restriction Enzyme
Am. J. Pathol., May 1, 2007; 170(5): 1739 - 1749.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. A. Kay, I. R. Ellis, S. J. Jones, S. Perrier, M. M. Florence, A. M. Schor, and S. L. Schor
The Expression of Migration Stimulating Factor, a Potent Oncofetal Cytokine, Is Uniquely Controlled by 3'-Untranslated Region-Dependent Nuclear Sequestration of Its Precursor Messenger RNA
Cancer Res., December 1, 2005; 65(23): 10742 - 10749.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. D. Amatangelo, D. E. Bassi, A. J.P. Klein-Szanto, and E. Cukierman
Stroma-Derived Three-Dimensional Matrices Are Necessary and Sufficient to Promote Desmoplastic Differentiation of Normal Fibroblasts
Am. J. Pathol., August 1, 2005; 167(2): 475 - 488.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.